Molecular mechanisms of death in cells with defective apoptotic pathways
Molecular mechanisms of death in cells with defective apoptotic pathways
批准号:
nhmrc : 454506
负责人:
A/Pr Nigel Waterhouse
金额:
$22.34万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2007
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2007-01-01 至 2009-12-31
中文摘要
人体通过杀死任何有可能成为肿瘤的细胞来保护自己免受癌症的侵袭。人体通过精心安排的一系列事件来杀死这些细胞,然而许多癌细胞在细胞死亡途径上存在缺陷,这使得它们能够存活下来,尽管它们被告知要死亡。在这项提案中,我们制定了一个研究计划,以调查如何杀死不想死亡的癌细胞。各种肿瘤细胞已被证明具有增加的水平的Bcl-2,这是一种原癌基因,阻止细胞死亡由不同的刺激。过度表达Bcl-2的细胞也对细胞毒药物产生抗药性。了解如何绕过Bcl-2(或阻止肿瘤中细胞死亡的蛋白质)将有助于更好地了解细胞死亡-细胞存活,并使我们能够探索为癌症细胞中发现特定死亡途径缺陷的患者量身定做治疗的可能性。细胞毒性淋巴细胞(CL)是免疫系统中的细胞,通过特异性地攻击和杀死肿瘤细胞来保护身体免受癌症的侵袭。我们一直在对CL:肿瘤相互作用进行开创性的研究,在这些研究中,我们可以定义细胞死亡中关键事件的形态和动力学,并表明CL具有杀死过度表达Bcl-2的靶细胞的能力。按照这一建议的目标,我们将了解细胞毒性淋巴细胞杀死在经典细胞死亡途径中存在缺陷的靶细胞的机制。因此,这些研究将确定在优先细胞死亡途径的一个关键组成部分不起作用的情况下细胞死亡的替代途径。由于细胞毒淋巴细胞可通过多种方式杀伤靶细胞,而肿瘤细胞死亡途径中可能存在多种缺陷,我们将探讨哪些是细胞死亡途径中的关键缺陷,或多种缺陷的组合,以防止细胞毒性淋巴细胞介导的细胞死亡,并允许肿瘤在体内存活。
英文摘要
The body protects itself from cancer by killing any cell that poses a risk of becoming a tumour. The body kills these cells via a carefully orchestrated sequence (or pathway) of events, however many cancer cells have defects in cell death pathways that has permitted them to survive even though they have been told to die. In this proposal we set out a research program to investigate how to kill cancer cells that don't want to die. Various tumour cells have been shown to have increased levels of Bcl-2, a proto-oncogene that blocks cell death induced by diverse stimuli. Cells that over-express Bcl-2 are also resistant to cytotoxic drugs. Understanding how to bypass Bcl-2 (or proteins that block cell death in tumours) will lead to a better understanding of cell death-cell survival and allow us to explore the possibility of tailoring treatment for patients in which specific defects in death pathways have been identified in their cancer cells. Cytotoxic lymphocytes (CL) are cells of the immune system that defend the body from cancer by specifically attacking and killing tumor cells. We have been pioneering studies of CL:tumour interactions in which we can define the morphology and kinetics of critical events in cell death and have shown that CL have the ability to kill target cells that over-express Bcl-2. Following the aims in this proposal, we will understand the mechanisms by which cytotoxic lymphocytes kill target cells that have defects in classical cell death pathways. These studies will therefore define alternative pathways to cell death in the event that a key component of the preferential pathway to cell death is inoperative. Since cytotoxic lymphocytes use a variety of ways to kill their targets and tumors may contain multiple defects in cell death pathways, we will explore which are the key defects, or the combination of multiple defects, in cell death pathways that prevent cytotoxic lymphocyte mediated cell death and permit tumour survival in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating mitochondrial outer membrane permeabilization during programmed cell death
-
批准号:nhmrc : 566706
-
项目类别:Career Development Fellowships
-
资助金额:$5.87万
-
财政年份:2009
-
负责人:A/Pr Nigel Waterhouse
-
依托单位:
Regulation of leukocyte lifespan by granzyme B and PI-9
-
批准号:nhmrc : 491176
-
项目类别:NHMRC Project Grants
-
资助金额:$54.46万
-
财政年份:2008
-
负责人:A/Pr Nigel Waterhouse
-
依托单位:
Mechanisms of CL mediated cell death; integration of multiple cell death pathways
-
批准号:nhmrc : 359232
-
项目类别:Career Development Fellowships
-
资助金额:$26.59万
-
财政年份:2005
-
负责人:A/Pr Nigel Waterhouse
-
依托单位:
Mechanisms of CTL mediated caspase independent cell death
-
批准号:nhmrc : 165405
-
项目类别:Early Career Fellowships
-
资助金额:$14.4万
-
财政年份:2001
-
负责人:A/Pr Nigel Waterhouse
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Exploring the Intrinsic Mechanisms of CEO Turnover and Market
-
批准号:--
-
项目类别:外国学者研究基金
-
资助金额:--
-
批准年份:2024
-
负责人:HAOFEI Z
-
依托单位:
Exploring the Intrinsic Mechanisms of CEO Turnover and Market Reaction: An Explanation Based on Information Asymmetry
-
批准号:W2433169
-
项目类别:外国学者研究基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:HAOFEI ZHANG
-
依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
-
批准号:82371255
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹立
-
依托单位:
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
-
批准号:82370979
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张善勇
-
依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
-
批准号:82370981
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:陈敏洁
-
依托单位:
Idh3a作为线粒体代谢—表观遗传检查点调控产热脂肪功能的机制研究
-
批准号:82370851
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:包玉倩
-
依托单位:
小脑浦肯野细胞突触异常在特发性震颤中的作用机制及靶向干预研究
-
批准号:82371248
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:吴逸雯
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位:
声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
-
批准号:82371973
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:孙迪
-
依托单位:
用于小尺寸管道高分辨成像荧光聚合物点的构建、成像机制及应用研究
-
批准号:82372015
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:熊丽琴
-
依托单位: